Pediatric Drugs

, Volume 5, Issue 3, pp 151–165

Treatment of Infectious Diarrhea in Children

Therapy In Practice


Diarrheal diseases remain an important cause of childhood morbidity and death in developing countries, although diarrheal deaths have significantly declined in recent years, mostly due to successes in the implementation of oral rehydration therapy (ORT), which is the principal treatment modality.

Diarrhea may occur for varied reasons; however, most episodes of diarrhea in developing countries are infectious in origin. Three clinical forms of diarrhea (acute watery diarrhea, invasive diarrhea, and persistent diarrhea) have been identified to formulate a management plan. Acute diarrhea may be watery (where features of dehydration are prominent) or dysenteric (where stools contain blood and mucus).

Rehydration therapy is the key to management of acute watery diarrhea, whereas antimicrobial agents play a vital role in the management of acute invasive diarrhea, particularly shigellosis and amebiasis. In persistent diarrhea, nutritional therapy, including dietary manipulations, is a very important aspect in its management, in addition to rehydration therapy. Rehydration may be carried out either by the oral or intravenous route, depending upon the degree of dehydration. Oral rehydration salts (ORS) solution (World Health Organization formula) is recommended for ORT. Intravenous fluid is recommended for initial management of severe dehydration due to diarrhea, followed by ORT with ORS solution for correction of ongoing fluid losses. Antimicrobial therapy is beneficial for cholera and shigellosis. Antiparasitic agents are indicated only if amebiasis and giardiasis are present.

Appropriate feeding during diarrhea is recommended for nutritional recovery and to prevent bodyweight loss. Antidiarrheal agents do not provide additional benefit in the management of infectious diarrhea. Although some probiotics have been shown to be beneficial in the treatment of acute diarrhea due to rotavirus, their use in the treatment of diarrhea is yet to be recommended, even in developed countries. The children of developing countries might benefit from zinc supplementation during the diarrheal illness, but its mode of delivery and cost effectiveness are yet to be decided.


  1. 1.
    Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull World Health Organ 1982; 60(4): 605–13PubMedGoogle Scholar
  2. 2.
    Victora CG, Bryce J, Fontaine O, et al. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78(10): 1246–55PubMedGoogle Scholar
  3. 3.
    Fine KD, Krejs GJ, Fordtran JS. Diarrhoea. In: Steisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology diagnosis management. 4th ed. Vol. 1. Philadelphia (PA): WB Saunders, 1989: 290–316Google Scholar
  4. 4.
    Rodriguez WJ, Kim HW, Brandt CD, et al. Rotavirus gastroenteritis in the Washington, DC, area: incidence of cases resulting in admission to the hospital. Am J Dis Child 1980; 134(8): 777–9PubMedGoogle Scholar
  5. 5.
    Fishman PH. Mechanism of action of cholera toxin: events on the cell surface. In: Field M, Fordtran JS, Schultz SG, editors. Secretory diarrhoea. Bethesda (MD): American Physiological Society, 1980: 85–106Google Scholar
  6. 6.
    Alam NH, Majumder RN, Fuchs GJ. The efficacy and safety of a reduced osmolarity oral rehydration solution in adults with cholera. CHOICE Study Group. Lancet 1999; 354(91175): 296–9PubMedCrossRefGoogle Scholar
  7. 7.
    CHOICE Study Group. Multicenter, ranzomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhoea. Pediatrics 2001; 107(4): 613–8CrossRefGoogle Scholar
  8. 8.
    Treatment of diarrhoea: a manual for physicians and other senior health workers. Geneva: World Health Organization, 1990. Report no. WHO/CDR/SER/95.3Google Scholar
  9. 9.
    Guarino A, Albano F. Guidelines for the approach to outpatient children with acute diarrhoea. Acta Paediatr 2001; 90(10): 1087–95PubMedCrossRefGoogle Scholar
  10. 10.
    Zodpey SP, Deshpande SG, Ughade SN, et al. Risk factors for development of dehydration in children aged under five who have acute watery diarrhoea: a case control study. Public Health 1998; 112(4): 233–6PubMedGoogle Scholar
  11. 11.
    Faruque ASG, Mahalanabis D, Islam A, et al. Common diarrhoeal pathogens and the risk of dehydration in young children with acute watery diarrhoea: a case control study. Am J Trop Med Hyg 1993; 49(1): 93–100PubMedGoogle Scholar
  12. 12.
    Programme for the control of diarrhoeal disease: a manual for the treatment of diarrhoea for use by physicians and other senior health workers. Geneva: World Health Organization, 1990. Report no. WHO/CDD/SER/80.2 Rev. 2Google Scholar
  13. 13.
    Reduced osmolarity oral rehydration salts (ORS) formulation: a report from a meeting of experts jointly organized by UNICEF and WHO, Unicef House, New York, USA, on 18 July 2001. Geneva: World Health Organization, Child and Adolescent Health and Development, 2001. Report no. WHO/FCH/ CAH/01.22Google Scholar
  14. 14.
    Ahmed T, Ali M, Ullah MM, et al. Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. Lancet 1999; 353(9168): 1919–22PubMedCrossRefGoogle Scholar
  15. 15.
    Ahmed T, Begum B, Badiuzzaman AM, et al. Management of severe malnutrition and diarrhoea. Indian J Pediatr 2001; 68(1): 45–51PubMedCrossRefGoogle Scholar
  16. 16.
    Cash RA, Toha KM, Nalin DR, et al. Acetate in the correction of acidosis secondary to diarrhoea. Lancet 1969; II(761): 302–3CrossRefGoogle Scholar
  17. 17.
    Molla A, Molla AM, Sarker SA, et al. Whole-gut transit time and its relationship to absorption of macronutrients during diarrhoea and after recovery. Scand J Gastroenterol 1983; 18(4): 537–43PubMedCrossRefGoogle Scholar
  18. 18.
    Roy SK, Haider R, Akbar MS, et al. Persistent diarrhoea: clinical efficacy and nutrient absorption with a rice-based diet. Arch Dis Child 1990; 65(3): 294–7PubMedCrossRefGoogle Scholar
  19. 19.
    Rees L, Brook CG. Gradual reintroduction of full strength milk after acute gastroenteritis in children. Lancet 1979; I(8119): 770–1CrossRefGoogle Scholar
  20. 20.
    Brown KH, Gastanaduz AS, Saavedra JM. Effect of continued oral feeding on clinical and nutritional outcomes of acute diarrhoea in children. J Pediatr 1998; 112: 191–200Google Scholar
  21. 21.
    Readings on diarrhoea: students manual. Dhaka: Director General of Health Services, Ministry of Health and Family Welfare, Government of Bangladesh, 1994: 45Google Scholar
  22. 22.
    Mazumder RN, Ashraf H, Hoque SS, et al. Effect of an energy-dense diet on the clinical course of acute shigellosis in undernourished children. Br J Nutr 2000; 84: 775–9PubMedGoogle Scholar
  23. 23.
    Bennish M, Eusof A, Kay B, et al. Multi-resistant shigella infections in Bangladesh [letter]. Lancet 1985; II: 441CrossRefGoogle Scholar
  24. 24.
    Tong MJ, Martin DG, Cunningham JJ, et al. Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA 1970; 214: 1841–4PubMedCrossRefGoogle Scholar
  25. 25.
    Salam MA, Bennish ML. Therapy for shigellosis: randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113: 901–7PubMedCrossRefGoogle Scholar
  26. 26.
    Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of shigella isolates in Bangladesh, 1983–1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14(5): 1055–60PubMedCrossRefGoogle Scholar
  27. 27.
    Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in shigella dysenteriae type 1. Lancet 1987; II: 419–21CrossRefGoogle Scholar
  28. 28.
    Ashkenazi S, Cleary TG, Pickering LK. Bacterial toxins associated with diarrhoeal disease. In: Lebenthal E, Duffey ME, editors. Textbook of secretory diarrhoea. New York: Raven Press Ltd, 1990: 255–72Google Scholar
  29. 29.
    Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5(5): 607–25PubMedCrossRefGoogle Scholar
  30. 30.
    Kiessling CR, Cutting JH, Loftis M, et al. Antimicrobial resistance of food-related salmonella isolates 1999–2000. J Food Prot 2002; 65(4): 603–8PubMedGoogle Scholar
  31. 31.
    Rigothier MC, Khun H, Tavares P, et al. Fate of entamoeba histolytica during establishment of amoebic liver abscess analyzed by quantitative radio imaging and histology. Infect Immun 2002; 70(6): 3208–15PubMedCrossRefGoogle Scholar
  32. 32.
    Bruchhaus I, Roeder T, Lotter H, et al. Differential gene expression in entamoeba histolytica isolated from amoebic liver abscess. Mol Microbiol 2002; 44(4): 1063–72PubMedCrossRefGoogle Scholar
  33. 33.
    Shamsuzzaman SM, Hashiguchi Y. Thoracic amoebiasis. Clin Chest Med 2002; 23(2): 479–92PubMedCrossRefGoogle Scholar
  34. 34.
    Kulkarni H, Goldwater PN, Martin A, et al. Escherichia coli ‘O’ group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis 2002; 25(4): 249–68PubMedCrossRefGoogle Scholar
  35. 35.
    Persistent diarrhoea in children in developing countries: memorandum from a WHO meeting. Bull World Health Organ 1988; 66(6): 709–17Google Scholar
  36. 36.
    Back RE, Brown KH, Becker S. Malnutrition is a determining factor in diarrhoeal duration, but not incidence, among young children in a longitudinal study in rural Bangladesh. Am J Clin Nutr 1984; 39(1): 87–94Google Scholar
  37. 37.
    Wallen-Smith JA, Nazar H, Manuel P, et al. Protein intolerance as a cause of postentenitis diarrhoea. In: Lebenthal E, editor. Chronic diarrhoea in children. New York: Raven Press, 1984: 407–23Google Scholar
  38. 38.
    International Working Group on Persistent Diarrhoea. Evaluation of an algorithm for the treatment of persistent diarrhoea: a multicentre study. Bull World Health Organ 1996; 74(5): 479–89Google Scholar
  39. 39.
    Ashraf H, Ahmed S, Fuchs GJ, et al. Persistent diarrhoea: associated infection and response to a low lactose diet. J Trop Pediatr 2002; 48: 142–8PubMedCrossRefGoogle Scholar
  40. 40.
    Management of the child with a serious infection or severe malnutrition. Geneva: World Health Organization, 2000Google Scholar
  41. 41.
    The rational use of drugs in the management of acute diarrhoea in children. Geneva: World Health Organization, 1990: 12Google Scholar
  42. 42.
    Dupont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973 Dec; 226(13): 1525–8PubMedCrossRefGoogle Scholar
  43. 43.
    Curtis JA, Goel KM. Lomotil poisoning in children. Arch Dis Child 1979; 54(3): 222–5PubMedCrossRefGoogle Scholar
  44. 44.
    Rumack BH, Temple AR. Lomotil poisoning. Pediatrics 1974; 53(4): 495–500PubMedGoogle Scholar
  45. 45.
    Kassem AS, Madkour AA, Massoud BZ, et al. Loperamide in acute childhood diarrhoea: a double blind controlled trial. J Diarrhoeal Dis Res 1983; 1(1): 10–6PubMedGoogle Scholar
  46. 46.
    Karrar ZA, Abdullah MA, Moody JB, et al. Loperamide in acute diarrhoea in childhood: results of a double blind, placebo controlled clinical trial. Ann Trop Paediatr 1987; 7(2): 122–7PubMedGoogle Scholar
  47. 47.
    Diarrhoeal Disease Study Group. Loperanmide in acute diarrhoea in childhood: results of double blind, placebo controlled multicentre clinical trial. BMJ 1984; 289: 1263–7CrossRefGoogle Scholar
  48. 48.
    Murtaza A, Khan SR, Butt KS, et al. Paralytic ileus: a serious complication in acute diarrhoeal disease among infants in developing countries. Acta Paediatr Scand 1989; 78(5): 701–5PubMedCrossRefGoogle Scholar
  49. 49.
    Bhutta TI, Tahir KI. Loperamide poisoning in children [letter]. Lancet 1990; 335: 363PubMedCrossRefGoogle Scholar
  50. 50.
    Minton NA, Henry JA. Loperamide poisoning in children [letter]. Lancet 1990; 335: 788PubMedCrossRefGoogle Scholar
  51. 51.
    Smith PL, Field M. In vitro antisecretory effects of trifluoperazine and other neuroleptics in rabbit and human small intestine. Gastroenterology 1980; 78(6): 1545–53PubMedGoogle Scholar
  52. 52.
    Holmgren J, Lange S, Lonnroth I. Reversal of cyclic AMP-mediated intestinal secretion in mice by chlorpromazine. Gastroenterology 1978; 75(6): 1103–8PubMedGoogle Scholar
  53. 53.
    Lonnroth I, Holmgren J, Lange S. Chlorpromazine inhibits cholera toxin-induced intestinal hypersecretion. Med Biol 1977; 55(3): 126–9PubMedGoogle Scholar
  54. 54.
    Rabbani GH, Greenough III WB, Holmgren J, et al. Chlorpromazine reduces fluid loss in cholera. Lancet 1979; I: 410–2CrossRefGoogle Scholar
  55. 55.
    Rabbani GH, Butler T, Bardhan PK, et al. Reduction of fluid loss in cholera by nicotinic acid: a randomized controlled trial. Lancet 1983; II(8365–66): 1439–42CrossRefGoogle Scholar
  56. 56.
    Islam A, Bardhan PK, Islam MR, et al. A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. Trop Geogr Med 1986; 38(3): 221–5PubMedGoogle Scholar
  57. 57.
    Rabbani GH, Butler T. Indomethacin and chloroquine fail to inhibit fluid loss in cholera. Gastroenterology 1985; 89(5): 1035–7PubMedGoogle Scholar
  58. 58.
    Molla AM, Gyr K, Bardhan PK, et al. Effect of intravenous somatostatin on stool output in diarrhoea due to vibrio cholera. Gastroenterology 1985; 87(4): 845–7Google Scholar
  59. 59.
    Primi MP, Bueno L, Baumer P, et al. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther 1999; 13Suppl. 6: 3–7PubMedCrossRefGoogle Scholar
  60. 60.
    Krejs GJ. Acetorphan prevents cholera toxin induced water and electrolyte secretion in the human jejunum. Gastroenterology 1979; 9: 887–91Google Scholar
  61. 61.
    Bergmann JF, Chaussade S, Couturier D, et al. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 1992; 6(3): 305–13PubMedCrossRefGoogle Scholar
  62. 62.
    Hamza H, Ben Khalifa H, Baumer P, et al. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment Pharmacol Ther 1999; 13Suppl. 6: 15–9PubMedGoogle Scholar
  63. 63.
    Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, et al. Racecadotril in the treatment of acute diarrhoea in children. N Engl J Med 2000; 343: 463–7PubMedCrossRefGoogle Scholar
  64. 64.
    Cezard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerability of racecadotril in acute diarrhoea in children. Gastroenterology 2001; 120: 799–805PubMedCrossRefGoogle Scholar
  65. 65.
    Sarker SA, Casswall TH, Mahlanabis D, et al. Successful treatment of rotavirus diarrhoea in children with immunoglobulin from immunized bovine colostrums. Pediatr Infect Dis J 1998; 17: 1149–54PubMedCrossRefGoogle Scholar
  66. 66.
    Sarker SA, Casswall TH, Juneja LR, et al. Randomized, placebo-controlled clinical trial of hyperimmunized chicken egg yolk immunuglobulin in children with rotavirus diarrhoea. J Pediatr Gastroenterol Nutr 2001; 32: 19–25PubMedCrossRefGoogle Scholar
  67. 67.
    Mitra AK, Mahalanabis D, Ashraf H, et al. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double blind, controlled clinical trial. Acta Pediatr 1995; 84: 996–1001CrossRefGoogle Scholar
  68. 68.
    Casswall TH, Sarkar SA, Faruque SM, et al. Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobin milk concentrate from hyperimmunised cows: a double blind, placebo controlled, clinical trial. Scand J Gastroenterol 2000; 35(7): 711–8PubMedCrossRefGoogle Scholar
  69. 69.
    Ashraf H, Mitra AK, Mahalanabis D, et al. Hyperimmune bovine colostrums in the treatment of shigellosis in children: a double blind, randomized, controlled trial. Acta Pediatr 2001; 90: 1–6Google Scholar
  70. 70.
    Brussow H, Hilpert H, Walther I, et al. Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol 1987; 25(6): 982–6PubMedGoogle Scholar
  71. 71.
    Guarino A, Casola A, Bruzzese E, et al. Human serum immunoglobulin counteracts rotaviral infection in Caco-2 cells. Pediatr Res 1996; 40(6): 881–7PubMedCrossRefGoogle Scholar
  72. 72.
    Salminen S, Bouley C, Boutron Ruault MC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80Suppl. 1: S147–71PubMedCrossRefGoogle Scholar
  73. 73.
    Raza S, Graham SM, Allen SJ, et al. Lactobacillus GG promotes recovery from acute non-bloody diarrhoea in Pakistan. Pediatr Infect Dis J 1995; 14(2): 107–11PubMedCrossRefGoogle Scholar
  74. 74.
    Isolauri E, Juntunen M, Rautanen T, et al. A human lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhoea in children. Pediatrics 1991; 88: 90–7PubMedGoogle Scholar
  75. 75.
    Shornikova AV, Cassa IA, Mykkanen H, et al. Bacteriotherapy with lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997; 16(12): 1103–7PubMedCrossRefGoogle Scholar
  76. 76.
    Guarino A, Canani RB, Spagnuolo MI, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhoea. J Pediatr Gastroenterol Nutr 1997; 25(5): 516–9PubMedCrossRefGoogle Scholar
  77. 77.
    Colombel JF, Cortot A, Neut C, et al. Yoghurt with bifdobacterium longum reduces erythromycin-induced gastrointestinal effects [letter]. Lancet 1987; II(8549): 43CrossRefGoogle Scholar
  78. 78.
    Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yogurt in prevention of antibiotic associated diarrhoea. Ann Med 1990; 22(1): 57–9PubMedCrossRefGoogle Scholar
  79. 79.
    Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhoea by a human Lactobacillus strain. Pediatr Res 1992; 32(2): 41–2CrossRefGoogle Scholar
  80. 80.
    Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr 1987; 45Suppl. 5: 1243–55PubMedGoogle Scholar
  81. 81.
    Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982; 83(2): 424–9PubMedGoogle Scholar
  82. 82.
    Sakata T. Effects of indigestible dietary bulk and short chain fatty acids on the tissue weight and epithelial cell proliferation rate of the digestive tract in rats. J Nutr Sci Vitaminol (Tokyo) 1986; 32(4): 355–62CrossRefGoogle Scholar
  83. 83.
    Roediger WE, Rae DA. Trophic effect of short chain fatty acids on mucosal handling of ions by the defunctioned colon. Br J Surg 1982; 69(1): 23–5PubMedCrossRefGoogle Scholar
  84. 84.
    McNeil NI, Cummings JH, James WP. Short-chain fatty acid absorption by the human large intestine. Gut 1978; 9: 819–22CrossRefGoogle Scholar
  85. 85.
    Ruppin H, Bar-Meier S, Soergel KH. Absorption of short-chain fatty acids (SCFAs) by the colon. Gastroenterology 1980; 78(6): 1500–7PubMedGoogle Scholar
  86. 86.
    Argenzio RA, Miller N, Von Engelhardt W. Effect of volatile fatty acids on water and ion absorption from the goat colon. Am J Physiol 1975; 229(4): 997–1002PubMedGoogle Scholar
  87. 87.
    Roediger WE, Moore A. Effect of short-chain fatty acids on sodium absorption in isolated human colon perfused through vascular bed. Dig Dis Sci 1981; 26(2): 100–6PubMedCrossRefGoogle Scholar
  88. 88.
    Binder HJ, Mehta P. Short chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology 1989; 96(4): 989–96PubMedGoogle Scholar
  89. 89.
    Ramakrishna BS, Mathan VI. Colonic dysfunction in acute diarrhoea: the role of luminal short chain fatty acids. Gut 1993; 34(9): 1215–8PubMedCrossRefGoogle Scholar
  90. 90.
    Speelman P, Butler T, Kabir I, et al. Colonic dysfunction during cholera infection. Gastroenterology 1986; 91(5): 1164–70PubMedGoogle Scholar
  91. 91.
    Gore SM, Fontaine O, Pierce NF. Impact of rice based oral rehydration solution on stool output and duration of diarrhoea: meta-analysis of 13 clinical trials. BMJ 1992; 304(6822): 287–91PubMedCrossRefGoogle Scholar
  92. 92.
    Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000; 342(5): 308–13PubMedCrossRefGoogle Scholar
  93. 93.
    Alam NH, Meier R, Scheinder H, et al. Partially hydrolyzed guar gum supplemented oral rehydration solution in the treatment of acute diarrhoea in children. J Pediatr Gastroenterol Nutr 2000; 31: 503–57PubMedCrossRefGoogle Scholar
  94. 94.
    Alam NH, Meier RF, Sarker SA, et al. Evaluation of the effect of a soluble fiber (Benefiber) supplemented comminuted chicken based diet in the treatment of persistent diarrhoea. Gastroenterology 2001; 120Suppl. 1: A–1111Google Scholar
  95. 95.
    Rabbani GH, Teka T, Zaman B, et al. Clinical studies in persistent diarrhoea: dietary management with green banana or pectin in Bangladesh children. Gastroenterology 2001; 121(3): 554–60PubMedCrossRefGoogle Scholar
  96. 96.
    Fontaine O. Effect of zinc supplementation on clinical course of acute diarrhoea. J Health Popul Nutr 2001; 19(4): 339–46PubMedGoogle Scholar
  97. 97.
    Haffejee IE. Effect of oral folate on duration of acute diarrhoea. Lancet 1988; II: 334–5CrossRefGoogle Scholar
  98. 98.
    Haffejee IE. Folate for diarrhoea. Dialogue Diarrhoea 1990; 43: 2Google Scholar
  99. 99.
    Ashraf H, Rahman MM, Fuchs GJ, et al. Folic acid in the treatment of acute watery diarrhoea in children: a double-blind, randomized, controlled trial. Acta Paediatr 1998; 87: 1113–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.International Centre for Diarrhoeal Disease ResearchCentre for Health and Population ResearchDhakaBangladesh
  2. 2.Clinical Sciences DivisionICDDR,BDhakaBangladesh

Personalised recommendations